Pasithea Therapeutics Corp.
KTTA
$0.77
-$0.03-4.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.35M | 1.75M | 1.66M | 1.95M | 1.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.09M | 3.11M | 3.81M | 3.68M | 3.26M |
| Operating Income | -6.09M | -3.11M | -3.81M | -3.68M | -3.26M |
| Income Before Tax | -10.11M | -3.04M | -3.72M | -3.56M | -3.18M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.11M | -3.04M | -3.72M | -3.56M | -3.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.11M | -3.04M | -3.72M | -3.56M | -3.18M |
| EBIT | -6.09M | -3.11M | -3.81M | -3.68M | -3.26M |
| EBITDA | -5.93M | -2.93M | -3.65M | -3.52M | -3.10M |
| EPS Basic | -0.79 | -0.41 | -0.66 | -1.61 | -2.53 |
| Normalized Basic EPS | -0.29 | -0.26 | -0.41 | -1.01 | -1.58 |
| EPS Diluted | -0.79 | -0.41 | -0.66 | -1.61 | -2.53 |
| Normalized Diluted EPS | -0.29 | -0.26 | -0.41 | -1.01 | -1.58 |
| Average Basic Shares Outstanding | 12.77M | 7.44M | 5.64M | 2.21M | 1.25M |
| Average Diluted Shares Outstanding | 12.77M | 7.44M | 5.64M | 2.21M | 1.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |